Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
|
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib
    Kunte, Siddharth
    Stevenson, James
    CLINICAL LUNG CANCER, 2021, 22 (03) : E298 - E300
  • [42] CrizotinibDevelopment of crizotinib-resistance in lung adenocarcinoma: case report
    Reactions Weekly, 2017, 1635 (1) : 96 - 96
  • [43] Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis A Case Report
    Wang, Wenxian
    Wu, Wei
    Zhang, Yiping
    MEDICINE, 2016, 95 (30)
  • [44] Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
    Gao, Peng
    Tang, Kangning
    Hao, Yuqiu
    Li, Wei
    Lv, Xuejiao
    Li, Dapeng
    Jia, Yuxi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
    Kim, H. R.
    Lim, S. M.
    Kim, H. J.
    Hwang, S. K.
    Park, J. K.
    Shin, E.
    Bae, M. K.
    Ou, S. -H. I.
    Wang, J.
    Jewell, S. S.
    Kang, D. R.
    Soo, R. A.
    Haack, H.
    Kim, J. H.
    Shim, H. S.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2364 - 2370
  • [46] Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
    Liu, Junfang
    Shen, Lijun
    Qian, Yunyao
    Liu, Yunpeng
    Su, Minhong
    Yi, Li
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2931 - 2935
  • [47] Response to crizotinib and gefitinib in a lung adenocarcinoma patient harboring a concurrent EGFR exon 21 mutation and an ALK rearrangement.
    Bien-Willner, Gabriel Alejandro
    Yang, Dong
    McCanless, Christopher M.
    Mambo, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report
    Zhang, Na
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Xie, Zhi
    Wang, Bin-Chao
    Tu, Hai-Yan
    Jiang, Ben-Yuan
    Wu, Yi-Long
    ONCOLOGY LETTERS, 2014, 8 (06) : 2624 - 2626
  • [49] Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report
    Wang, Yu
    Chen, Zheng
    Han, Xiao
    Li, Jiamei
    Guo, Honglin
    Shi, Junping
    ONCOLOGIST, 2021, 26 (03): : 178 - 181
  • [50] Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: A case report
    Takakuwa, Osamu
    Oguri, Tetsuya
    Yokoyama, Midori
    Hijikata, Hisatoshi
    Uemura, Takehiro
    Ohkubo, Hirotsugu
    Maeno, Ken
    Niimi, Akio
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 121 - 123
12345